EMA approve UCB’s treatment Cimzia for psoriasis

European Medicines Agency has approved a label extension for UCB’s Cimzia allowing it to be used for treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The approval makes Cimzia, the first Fc-free, PEGylated anti-TNF treatment option for use in moderate-to-severe plaque psoriasis “and marks the entry of UCB into immuno-dermatology, where

Continue Reading

Nice set to collaborate with Greater Manchester to improve health of locals

A partnership between Greater Manchester and NICE that was created with the aim of improving the health of the local population has been extended for another three years. A Memorandum of Understanding has been agreed between NICE, Health Innovation Manchester and The University of Manchester outlining a shared commitment to boosting health through research, informing

Continue Reading

AstraZeneca’s lung cancer treatment has been approved by the EU for first line use in patients

AZ’s Tagrisso has been given a go-ahead in Europe for first-line use to treat EGFR-mutated non-small cell lung cancer (NSCLC), offering a new line of attack at this stage of the disease. The decision was based on clinical data from the Phase III FLAURA trial, showing that progression free survival in patients taking Tagrisso (osimertinib)

Continue Reading

Janssen’s Zytiga has been rejected by NICE for early treatment of aggressive prostate cancer

Experts state that it is looking highly unlikely that Janssen’s Zytiga plus androgen deprivation therapy (ADT) and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer.   NICE have published draft guidelines rejecting the therapy in this setting, after concluding that the company’s economic

Continue Reading

European Commission approves Amgen’s Repatha for reducing cardiovascular risk

The EC has decided to expand the scope of Amgen’s PCSK9 inhibitor Repatha to include the reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease (CVD). The treatment can be used to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels – as an adjunct to correction of other risk factors. The

Continue Reading

US regulatory body grants Merck & co’s Keytruda priority review

FDA has accepted Merck & Co’s anti-PD-1 therapy, Keytruda,  in combination with Eli Lilly’s pemetrexed and platinum chemotherapy as a first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC). The regulators has also granted Priority Review to this application. This supplemental application is based on overall survival and progression-free survival (PFS) data

Continue Reading